



### Learning Objectives by Session- Provincial Cancer Care Conference 2023

Session	Speaker(s)	Learning Objectives <i>By the end of the session, participants will be able to...</i>
Trauma-Informed Care	Jocelyne Lalonde	<ol style="list-style-type: none"> <li>1. Discuss the prevalence and impact of trauma on individuals and families who are experiencing a cancer diagnosis.</li> <li>2. List five key trauma-informed principles.</li> <li>3. Describe practical strategies for implementing each of the trauma-informed principles and how this will fit into a framework for working with patients and families.</li> <li>4. Refer to examples and evidence that demonstrates why approaching work with the person with cancer and their families through a trauma-informed lens is beneficial.</li> </ol>
Practicing Trauma-Informed Care: An Interactive Skill-Building Workshop	Allison Wiens & Irene Maendel	<ol style="list-style-type: none"> <li>1. Describe how to identify trauma and different ways to ask about trauma.</li> <li>2. Identify barriers to trauma-informed care and ways to mitigate.</li> <li>3. Discuss ways to improve trauma-informed care in the various cancer care setting.</li> </ol>
How Understanding the Psychology of How We Think Can Remove Barriers to Inclusion and Equity	Dr. Rehman Abdulrehman	<ol style="list-style-type: none"> <li>1. Understand a cognitive behavioral model of human experience and change.</li> <li>2. Understand how our surrounding influence bias and ultimately racist marginalizing behavior.</li> <li>3. Understand the consequences of bias on mental health.</li> <li>4. Begin to identify personal steps to resolving personal issues that create barriers to inclusion.</li> </ol>
Lymphoma Work-Up and Overview	Dr. Catherine Moltzan	<ol style="list-style-type: none"> <li>1. State when the diagnosis of lymphoma should be suspected.</li> <li>2. Identify diagnosis and staging of lymphomas.</li> <li>3. Summarize the classification of lymphomas.</li> </ol>
Systemic Therapies for Lymphoma: Review and Updates	Dr. Pam Skrabek	<ol style="list-style-type: none"> <li>1. Identify common therapies in Hodgkin and Non-Hodgkin lymphoma.</li> </ol>

		<ol style="list-style-type: none"> <li>2. Discuss indications for Bruton Tyrosine Kinase inhibitors and give overview of novel BTKi.</li> <li>3. List different types of antibodies used in lymphoma and explain how bispecific antibodies work.</li> </ol>
Breaking Down Tumor Lysis	Dr. Mark Kristjanson	<ol style="list-style-type: none"> <li>1. Define the tumor lysis syndrome with reference to the Bishop-Cairo criteria.</li> <li>2. Describe those clinical circumstances which pose an especially high risk for tumor lysis, with reference to tumor histology and biology, and to patient comorbidities.</li> <li>3. Explain the approach to prevention and treatment for tumor lysis.</li> </ol>
A PEP Talk on Myeloma	Dr. Leonard Minuk	<ol style="list-style-type: none"> <li>1. Identify the indications for SPEP/FLC testing.</li> <li>2. How to interpret SPEP/FLC and follow up of monoclonal protein.</li> <li>3. Recognize the diagnosis of multiple myeloma.</li> </ol>
Multiple Myeloma Treatments Refresher	Dr. Emily Rimmer	<ol style="list-style-type: none"> <li>1. Explain the standard treatment options for transplant eligible and non-transplant eligible myeloma.</li> <li>2. State the common side effects and toxicities of treatments.</li> <li>3. Recognize the need for prophylactic treatments associated with different treatment regimens.</li> <li>4. Discuss new and emerging treatment options.</li> </ol>
Pain and Symptom Management for Multiple Myeloma	Dr. Cornelius Woelk	<ol style="list-style-type: none"> <li>1. Recognize the importance that symptom management plays throughout the course of a multiple myeloma illness.</li> <li>2. Describe three common effects of multiple myeloma, and their associated symptoms.</li> <li>3. Anticipate and manage common symptoms caused by multiple myeloma.</li> </ol>
Oncofertility: Caring for Your Patients	Mackenzie Jansen & Ian Scott	<ol style="list-style-type: none"> <li>1. Identify significant impacts of cancer treatments on fertility and recognize the importance of early intervention through fertility preservation.</li> <li>2. Identify and differentiate between various fertility preservation methods available for both male and female cancer patients, barriers to accessing FP, and solutions for Manitobans.</li> <li>3. Initiate discussions about fertility in a timely manner and gain insight into patient concerns that are sometimes left unspoken.</li> </ol>
Increasing Awareness about Colorectal Cancer Screening using Creative Strategies: The Giant Inflatable Colon Project	Tracy Abraham & Crystal Behrends	<ol style="list-style-type: none"> <li>1. Recognize how the Giant Inflatable Colon Project emerged as a creative initiative to engage with underserved populations, including rural residents and First Nations people.</li> </ol>

		<ol style="list-style-type: none"> <li>2. Identify how and where the Giant Inflatable Colon is used in communities to engage individuals in colorectal screening, prevention, and awareness.</li> <li>3. Identify the benefits and successes of the Giant Inflatable Colon Project to date.</li> </ol>
New Drugs for Breast Cancer	Dr. Marshall Pitz	<ol style="list-style-type: none"> <li>1. Identify current treatment pathways and medications for breast cancer.</li> <li>2. Differentiate recently approved breast cancer treatments from existing treatments in the context of treatment algorithms.</li> <li>3. Recognize the expected potential benefits of recently approved breast cancer treatments.</li> <li>4. Describe the main side effects of recently approved breast cancer treatments.</li> </ol>
Novel Therapies in Lung Cancer	Dr. Rebekah Rittberg	<ol style="list-style-type: none"> <li>1. Gain knowledge of new therapies used in lung cancer patients.</li> <li>2. Recognize the increasing use of therapies in early stage lung cancer.</li> <li>3. Understand treatment toxicities.</li> </ol>
Hypersensitivity at CancerCare: What's New?	Dr. Karver Zaborniak & Jodi Hyman	<ol style="list-style-type: none"> <li>1. Identify the fundamentals of allergic and infusion-related reactions.</li> <li>2. Discuss the recently implemented hypersensitivity protocols at CancerCare Manitoba.</li> <li>3. Consolidate and apply this knowledge to select patient scenarios.</li> </ol>
Hazardous vs. Non-Hazardous Drugs	Theresa Whiteside & Dana Augst	<ol style="list-style-type: none"> <li>1. Identify the difference between hazardous and non-hazardous drugs.</li> <li>2. Discuss safe handling precautions to minimize occupational risk.</li> <li>3. Teach appropriate patient education related to hazardous and non-hazardous safety precautions.</li> </ol>
Antibody Drug Conjugates	Blair Einarson	<ol style="list-style-type: none"> <li>1. Classify the three structural components of an antibody drug conjugate (ADC).</li> <li>2. Identify antibody drug conjugates used as systemic therapy at CancerCare Manitoba.</li> <li>3. List common toxicities associated with ADC treatment.</li> </ol>
On the Horizon: Emerging Drugs and Indications for Cancer Care	Danica Wasney	<ol style="list-style-type: none"> <li>1. Recognize at least 3 new indications for use and/or combinations of systemic therapies already listed on PODP Formulary.</li> <li>2. Name at least 3 new drugs anticipated for addition to the PODP Formulary in 2023/24.</li> <li>3. Identify place in therapy for new indications/drugs using the PODP Funding Algorithms.</li> </ol>
Treating the Whole Person	Dr. Debbie Whitney	<ol style="list-style-type: none"> <li>1. Reflect on circumstances that can bias clinicians to focus on only a limited aspect of the patient's experience.</li> </ol>

		<ol style="list-style-type: none"> <li>2. Recognize how a conceptual framework (several examples presented) can assist us to see the larger context.</li> <li>3. Identify some simple techniques for pausing and rebalancing in stressful moments.</li> </ol>
Mindfulness Based Stress Reduction: A Group Intervention for Cancer Patients and Their Families	Dr. Debbie Whitney & Kimberly Proch	<ol style="list-style-type: none"> <li>1. Identify the structure/contents of an 8-week Mindfulness Based Stress Reduction (MBSR) Program for cancer patients and families.</li> <li>2. Identify recent research on the effectiveness of MBSR for symptom reduction.</li> <li>3. Recognize how the practice of mindfulness can support clinician resilience.</li> </ol>
Research Plenary: Chimeric Antigen Receptor-T (CAR-T) Cells	Dr. David Szwajcer & Dr. Yale Michaels	<ol style="list-style-type: none"> <li>1. Identify what a CAR-T cell is and its potential role(s) in clinical medicine.</li> <li>2. Recognize the rationale for Setting up Point of Care CAR-T manufacturing in an academic facility.</li> <li>3. Summarize how to manufacture immune cells from pluripotential stem cells and how these cells could be used for clinical applications.</li> </ol>
CAR T-cell Therapy: coming soon to a province near you!	Dr. Chantalle Menard	<ol style="list-style-type: none"> <li>1. Summarize the status of the implementation process in Manitoba.</li> <li>2. Discuss the expanding indications for CAR T-cell therapy in hematologic malignancies.</li> <li>3. Discuss CAR T-cell clinical trial opportunities in Manitoba.</li> </ol>
Hepatitis B Reactivation during Cancer therapy: Risk and Preventive Strategies	Dr. Pam Skrabek	<ol style="list-style-type: none"> <li>1. Discuss the relevance of past and present viral Hepatitis B infection in patients with hematological conditions or cancer.</li> <li>2. Identify how to screen for Hepatitis B and reduce risk of reactivation while on cancer therapies.</li> </ol>
Cancer Surgery Quality in Manitoba	Dr. Pamela Hebbard	<ol style="list-style-type: none"> <li>1. Summarize the breadth of cancer surgeries done across the province.</li> <li>2. Identify areas of strength and improvement in the cancer surgery system.</li> <li>3. Recognize areas of improvement in cancer surgery.</li> </ol>

*Session details subject to change*